Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
0
Authors
Philip Kantoff
Philip Kantoff•Mark Frohlich•Paul Schellhammer
Published
July 29, 2010
Abstract
Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer.
